Vetintra - Company finances
|
EUR
|
2018
From: 2018-01-01
To: 2018-12-31
|
2019
From: 2019-01-01
To: 2019-12-31
|
2020
From: 2020-01-01
To: 2020-12-31
|
2021
From: 2021-01-01
To: 2021-12-31
|
2022
From: 2022-01-01
To: 2022-12-31
|
2023
From: 2023-01-01
To: 2023-12-31
|
2024
From: 2024-01-01
To: 2024-12-31
|
2025
From: 2025-01-01
To: 2025-12-31
|
|---|---|---|---|---|---|---|---|---|
|
Financial data
|
||||||||
| Sales revenue | 25,786 | 23,571 | 21,944 | 27,128 | 23,910 | 26,517 | 31,328 | 35,519 |
| Profit before tax | 899 | 684 | 143 | 200 | -1,376 | 46 | 180 | -4,735 |
| Net profit | 759 | 581 | 122 | 170 | -1,376 | 53 | 153 | -4,735 |
| Equity | -618 | 66 | 209 | 409 | -967 | -914 | -707 | -5,953 |
| Liabilities | 17,600 | 16,682 | 16,676 | 15,058 | 17,551 | 24,327 | 21,109 | 23,019 |
| Non-current assets | 5,844 | 5,844 | 5,844 | 5,844 | 5,844 | 5,844 | 5,844 | 4,858 |
| Current assets | 8,124 | 7,890 | 8,027 | 6,609 | 7,726 | 14,555 | 11,544 | 12,208 |
| Total assets | 13,968 | 13,734 | 13,871 | 12,453 | 13,570 | 20,399 | 17,388 | 17,066 |
|
Taxes paid
|
||||||||
| STI taxes | - | - | - | - | - | 1,938 | 3,664 | 3,372 |
|
Financial indicators
|
||||||||
| Revenue change y/y | +0.6% | -8.6% | -6.9% | +23.6% | -11.9% | +10.9% | +18.1% | +13.4% |
| ROA Return on Assets (ROA). The ratio of net profit to assets. Indicates the company's efficiency. | 5.4% | 4.2% | 0.9% | 1.4% | -10.1% | 0.3% | 0.9% | -27.7% |
| ROE Return on equity. The ratio of net profit to equity. Shows the return to shareholders. | - | 880.3% | 58.4% | 41.6% | - | - | - | - |
| Profit margin Net profit margin. Shows the overall profitability of the company. | 2.9% | 2.5% | 0.6% | 0.6% | -5.8% | 0.2% | 0.5% | -13.3% |
| EBT% EBT (Earnings Before Taxes) to revenue ratio. Shows the overall profitability of the company. | 3.5% | 2.9% | 0.7% | 0.7% | -5.8% | 0.2% | 0.6% | -13.3% |
| Liabilities/Equity The debt-to-equity ratio shows the company's capital structure. | - | 252.8 | 79.8 | 36.8 | - | - | - | - |
| Revenue per employee Ratio of revenue to the average annual number of employees. Indicates company efficiency. | 12,893 | 11,786 | 10,972 | 13,564 | 11,955 | 13,259 | 15,664 | 17,760 |
Sales revenue
See Scoris data in Google Search
Mark Scoris as a favorite source. One click, no registration.
Vetintra - Social security debts
The company had no debts to Sodra
Vetintra - VMI tax arrears
| From | To | Overdue, € |
|---|---|---|
| 2025-10-23 | 2025-10-30 | 0.01 |
| 2025-10-22 | 2025-10-22 | 0.2 |
| 2025-10-21 | 2025-10-21 | 44.56 |
| 2025-10-09 | 2025-10-20 | 44.36 |
VMI debt information has been collected since 2024-10-07. Debts for older periods will not be displayed.
Analysis of the company's financial position
This description was generated by artificial intelligence.
Report if inaccurate.
Vetintra, UAB (code 135689360) is a Private Limited Liability Company engaged in the retail sale of pharmaceutical products. In 2025, the company generated €35.5K in revenue, up 13.4% year on year and 34.0% over two years, showing continued sales growth. However, profitability weakened sharply: net profit turned into a €4.7K loss in 2025, compared with a €153 profit in 2024 and €53 in 2023, and the profit margin fell to -13.3%. The balance sheet also remained strained. Total assets stood at €17.1K at the end of 2025, while equity was negative at -€6.0K and liabilities amounted to €23.0K. Compared with 2024, assets decreased slightly and liabilities increased. Long-term assets were €4.9K and short-term assets €12.2K. Asset turnover was 2.08x, indicating relatively efficient use of the asset base for revenue generation. Revenue per employee reached €17.8K, while profit per employee was -€2.4K. Return measures are affected by the negative equity position, so profitability and capital strength should be viewed cautiously.